Literature DB >> 29352097

Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation.

Heinz Wiendl1, Peter A Calabresi2, Sven G Meuth2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29352097     DOI： 10.1212/WNL.0000000000004969

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.

Authors:  Jessica Frau; Francesco Saccà; Alessio Signori; Damiano Baroncini; Giuseppe Fenu; Pietro Annovazzi; Marco Capobianco; Elisabetta Signoriello; Alice Laroni; Sara La Gioia; Arianna Sartori; Giorgia Teresa Maniscalco; Simona Bonavita; Marinella Clerico; Cinzia Valeria Russo; Antonio Gallo; Caterina Lapucci; Antonio Carotenuto; Maria Pia Sormani; Eleonora Cocco
Journal:  J Neurol       Date:  2019-06-17       Impact factor: 4.849

Review 2.  [Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].

Authors:  Heinz Wiendl; Ralf Gold; Thomas Berger; Tobias Derfuss; Ralf Linker; Mathias Mäurer; Martin Stangel; Orhan Aktas; Karl Baum; Martin Berghoff; Stefan Bittner; Andrew Chan; Adam Czaplinski; Florian Deisenhammer; Franziska Di Pauli; Renaud Du Pasquier; Christian Enzinger; Elisabeth Fertl; Achim Gass; Klaus Gehring; Claudio Gobbi; Norbert Goebels; Michael Guger; Aiden Haghikia; Hans-Peter Hartung; Fedor Heidenreich; Olaf Hoffmann; Zoë R Hunter; Boris Kallmann; Christoph Kleinschnitz; Luisa Klotz; Verena Leussink; Fritz Leutmezer; Volker Limmroth; Jan D Lünemann; Andreas Lutterotti; Sven G Meuth; Uta Meyding-Lamadé; Michael Platten; Peter Rieckmann; Stephan Schmidt; Hayrettin Tumani; Martin S Weber; Frank Weber; Uwe K Zettl; Tjalf Ziemssen; Frauke Zipp
Journal:  Nervenarzt       Date:  2021-07-23       Impact factor: 1.214

3.  Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.

Authors:  Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Luigina Musu; Eleonora Cocco
Journal:  J Neurol       Date:  2019-03-12       Impact factor: 4.849

Review 4.  Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Authors:  Jan D Lünemann; Heinz Wiendl; Tobias Ruck; Paolo A Muraro; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2019-10-24       Impact factor: 42.937

5.  Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS.

Authors:  Katja Akgün; Nicole Kretschmann; Rocco Haase; Undine Proschmann; Hagen H Kitzler; Heinz Reichmann; Tjalf Ziemssen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-04-08

6.  Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.

Authors:  Nora Möhn; Steffen Pfeuffer; Tobias Ruck; Catharina C Gross; Thomas Skripuletz; Luisa Klotz; Heinz Wiendl; Martin Stangel; Sven G Meuth
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-11

7.  Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis.

Authors:  Katja Akgün; Judith Blankenburg; Michaela Marggraf; Rocco Haase; Tjalf Ziemssen
Journal:  Front Immunol       Date:  2020-01-31       Impact factor: 7.561

8.  Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.

Authors:  Heinz Wiendl; Matthew Carraro; Giancarlo Comi; Guillermo Izquierdo; Ho Jin Kim; Basil Sharrack; Carlo Tornatore; Nadia Daizadeh; Luke Chung; Alan K Jacobs; Richard J Hogan; Linda V Wychowski; Bart Van Wijmeersch
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.